Internal Medicine
| 5 min read
Stem cell therapy for Parkinson’s disease, discontinuation of Pfizer’s GLP-1 drug, a pig liver clinical trial, and more biotech and pharma news from this week.
| 5 min read
Insights from the AD/PD meeting, continued fallout from the FDA layoffs, hope for GLP-1 drugs in Alzheimer’s disease, and more led industry news this week.
| 4 min read
By using phages to deliver genes for therapeutic proteins, biologic drug delivery could become much easier.
| 10+ min read
The 2025 Breakthrough Prize in Life Sciences honors discoveries in GLP-1 drugs, multiple sclerosis, and DNA editing that transform human health.
| 4 min read
From layoffs at the FDA, CDC, and NIH to a blood test for Alzheimer’s disease and a starfish-inspired diagnostic, the DDN team breaks down this week’s news.
| 4 min read
A landmark UTI drug approval, new hope for the amyloid hypothesis in Alzheimer’s disease, a brewing vaccine study controversy, and more led the news this week.
| 2 min read
Antibiotics target bacteria, but new work in mice shows they also harm the mucus layer that protects the intestinal lining from microbes.
| 5 min read
From advances in graft versus host disease treatment to updates on H5N1 and Duchenne muscular dystrophy research, the DDN editors break down the news this week.
| 8 min read
Virus-inspired delivery methods enable gene editing of dysregulated microbes.
| 3 min read
Vertex Pharmaceuticals’ drug, Journavx, blocks a sodium channel outside of the brain. Experts hope that this non-addictive pain drug may be the first of many.
| 4 min read
DDN editors break down a surprising connection between microplastics and antimicrobial resistance, vitamin D for multiple sclerosis, obesity drugs updates, and more news from this week.
| 10+ min read
GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity, but they come with side effects. Physicians say the benefits outweigh the risks.
